Phaseline

Targets › PARP5B

PARP5B (Poly [ADP-ribose] polymerase tankyrase-2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. (UniProt, Q9H2K2)

Open in Phaseline: the race on PARP5B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eiji ShinozakiRK-582
Tankyrase (PARP-5a/b) inhibitor
PARP5A, PARP5BPhase 1Unresectable Colorectal Neoplasm MetastasisMar 2027

Conditions

Unresectable Colorectal Neoplasm Metastasis (1)

Modalities

small molecule (1)

Companies

Eiji Shinozaki (1)

Related targets

PARP5A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.